Follow a research candidate from first human exposure to larger comparisons without mistaking a phase label for proof.
Clinical development is often presented as a ladder from phase 1 to phase 3. That is a useful outline, but each stage asks different questions, and programmes can use combined or adaptive designs. A candidate does not become effective merely by reaching a numbered phase. Read the objective before the label: are researchers studying how a substance behaves in the body, testing an early signal of benefit, or comparing outcomes in a larger population? The phase tells you where to look, not what conclusion to reach.
The move from laboratory work to human exposure requires a reasoned package of information. FDA describes an Investigational New Drug application as including manufacturing information, earlier pharmacology and toxicology work, and a proposed clinical protocol. The purpose is to assess whether the planned research exposes people to unreasonable risk. This is a permission framework for an investigation, not approval to market the product as a proven treatment. When an article mentions an authorised trial, keep those two decisions separate in your notes.
Preparing the full guide…
The extended sections are available during your one-minute preview and with free email registration.
- Phase 1: learning about exposure and response
- Why early-trial safeguards matter
- Phase 2: a more specific benefit question
- Phase 3: larger and more confirmatory comparisons
- Review is distinct from trial completion
- Write a conclusion that fits the stage
Sources & further reading
Sources support specific statements, not every possible use of a molecule. Echo hub articles provide research background; original publications and official guidance are identified where supplied.
- FDA — Phase 1 IND frequently asked questions
- FDA — Investigational New Drug application
- FDA — Step 3: Clinical research
- EMA — Revised guideline on first-in-human clinical trials
- FDA — Drug development and review definitions